Gap finder
Search review questions
Each row is one question a systematic review asked: who, what, compared with what, and which outcome, with the effect it found and how certain that is. Words match anywhere in the field.
1,886 questions in 74 reviews · Skin
current versionsNo studies 542 · 28.7%Ungraded 130 · 6.9%Very low 326 · 17.3%Low 434 · 23%Moderate 348 · 18.5%High 106 · 5.6%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
| Question | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Metronidazole vs placebo Assessment of erythema or telangiectasia · Participants with rosacea Interventions for rosacea (2015) · Cochrane | no estimate extracted | 7 studies · 602 participants | Moderate |
Ciclosporin ophthalmic emulsion 0.05% vs artificial tears Participant‐assessed improvement in rosacea severity ‐ not measured · Participants with ocular rosacea Interventions for rosacea (2015) · Cochrane | no estimate extracted | NR | No studies |
Ciclosporin ophthalmic emulsion 0.05% vs artificial tears Proportion of participants with adverse event · Participants with ocular rosacea Interventions for rosacea (2015) · Cochrane | RR 2.32 [0.1, 53.42] | 1 study · 37 participants | Low |
Ciclosporin ophthalmic emulsion 0.05% vs artificial tears Physician‐assessed improvement in rosacea severity Schirmer score · Participants with ocular rosacea Interventions for rosacea (2015) · Cochrane | no estimate extracted | 1 study · 37 participants | Low |
Ciclosporin ophthalmic emulsion 0.05% vs artificial tears Assessment of erythema or telangiectasia ‐ not measured · Participants with ocular rosacea Interventions for rosacea (2015) · Cochrane | no estimate extracted | NR | No studies |
Ciclosporin ophthalmic emulsion 0.05% vs artificial tears Lesion count ‐ not measured · Participants with ocular rosacea Interventions for rosacea (2015) · Cochrane | no estimate extracted | NR | No studies |
Ciclosporin ophthalmic emulsion 0.05% vs artificial tears Time needed until improvement of the skin lesions ‐ not measured · Participants with ocular rosacea Interventions for rosacea (2015) · Cochrane | no estimate extracted | NR | No studies |
Ciclosporin ophthalmic emulsion 0.05% vs artificial tears Duration of remission ‐ not measured · Participants with ocular rosacea Interventions for rosacea (2015) · Cochrane | no estimate extracted | NR | No studies |
Clindamycin phosphate 1.2% + tretinoin 0.025% gel vs placebo HRQOL RosaQoL · Participants with rosacea Interventions for rosacea (2015) · Cochrane | no estimate extracted | 1 study · 83 participants | Moderate |
Clindamycin phosphate 1.2% + tretinoin 0.025% gel vs placebo Participant‐assessed improvement in rosacea severity ‐ not measured · Participants with rosacea Interventions for rosacea (2015) · Cochrane | no estimate extracted | NR | No studies |
Clindamycin phosphate 1.2% + tretinoin 0.025% gel vs placebo Proportion of participants with adverse event · Participants with rosacea Interventions for rosacea (2015) · Cochrane | RR 2.45 [1.42, 4.23] | 1 study · 83 participants | Moderate |
Metronidazole vs placebo Lesion count · Participants with rosacea Interventions for rosacea (2015) · Cochrane | no estimate extracted | 8 studies · 1964 participants | Moderate |
Clindamycin phosphate 1.2% + tretinoin 0.025% gel vs placebo Physician‐assessed improvement in rosacea severity PGA as defined by Wilkin 2004 · Participants with rosacea Interventions for rosacea (2015) · Cochrane | no estimate extracted | 1 study · 83 participants | Moderate |
Clindamycin phosphate 1.2% + tretinoin 0.025% gel vs placebo Assessment of erythema or telangiectasia · Participants with rosacea Interventions for rosacea (2015) · Cochrane | RR 1.71 [0.7, 4.18] | 1 study · 83 participants | Moderate |
Clindamycin phosphate 1.2% + tretinoin 0.025% gel vs placebo Lesion count · Participants with rosacea Interventions for rosacea (2015) · Cochrane | no estimate extracted | 1 study · 83 participants | Moderate |
Clindamycin phosphate 1.2% + tretinoin 0.025% gel vs placebo Time needed until improvement of the skin lesions ‐ not measured · Participants with rosacea Interventions for rosacea (2015) · Cochrane | no estimate extracted | NR | No studies |
Clindamycin phosphate 1.2% + tretinoin 0.025% gel vs placebo Duration of remission ‐ not measured · Participants with rosacea Interventions for rosacea (2015) · Cochrane | no estimate extracted | NR | No studies |
Tetracycline vs placebo HRQOL ‐ not measured · Participants with rosacea Interventions for rosacea (2015) · Cochrane | no estimate extracted | NR | No studies |
Tetracycline vs placebo Participant‐assessed improvement in rosacea severity · Participants with rosacea Interventions for rosacea (2015) · Cochrane | RR 1.48 [0.85, 2.57] | 1 study · 39 participants | Moderate |
Tetracycline vs placebo Proportion of participants with adverse event · Participants with rosacea Interventions for rosacea (2015) · Cochrane | RR 0.95 [0.06, 14.13] | 1 study · 39 participants | Moderate |
Tetracycline vs placebo Physician‐assessed improvement in rosacea severity · Participants with rosacea Interventions for rosacea (2015) · Cochrane | no estimate extracted | 2 studies · 107 participants | Moderate |
Tetracycline vs placebo Assessment of erythema or telangiectasia · Participants with rosacea Interventions for rosacea (2015) · Cochrane | no estimate extracted | 1 study · 39 participants | Moderate |
Metronidazole vs placebo Time needed until improvement of the skin lesions · Participants with rosacea Interventions for rosacea (2015) · Cochrane | no estimate extracted | 5 studies · 514 participants | High |
Tetracycline vs placebo Lesion count · Participants with rosacea Interventions for rosacea (2015) · Cochrane | no estimate extracted | 1 study · 39 participants | Moderate |
Tetracycline vs placebo Time needed until improvement of the skin lesions ‐ not measured · Participants with rosacea Interventions for rosacea (2015) · Cochrane | no estimate extracted | NR | No studies |
Tetracycline vs placebo Duration of remission ‐ not measured · Participants with rosacea Interventions for rosacea (2015) · Cochrane | no estimate extracted | NR | No studies |
Doxycycline 40 mg vs placebo HRQOL ‐ not measured · Participants with rosacea Interventions for rosacea (2015) · Cochrane | no estimate extracted | NR | No studies |
Doxycycline 40 mg vs placebo Participant‐assessed improvement in rosacea severity ‐ not measured · Participants with rosacea Interventions for rosacea (2015) · Cochrane | no estimate extracted | NR | No studies |
Doxycycline 40 mg vs placebo Proportion of participants with adverse event · Participants with rosacea Interventions for rosacea (2015) · Cochrane | no estimate extracted | 2 studies · 537 participants | High |
Doxycycline 40 mg vs placebo Physician‐assessed improvement in rosacea severity Investigator's Global Assessment, two point improvement · Participants with rosacea Interventions for rosacea (2015) · Cochrane | no estimate extracted | 2 studies · 537 participants | High |
Doxycycline 40 mg vs placebo Assessment of erythema or telangiectasia Clinician's Erythema Assessments scale 0 to 4 · Participants with rosacea Interventions for rosacea (2015) · Cochrane | no estimate extracted | 2 studies · 537 participants | High |
Doxycycline 40 mg vs placebo Lesion counts Scale from: ‐4.3 to ‐11.8 · Participants with rosacea Interventions for rosacea (2015) · Cochrane | no estimate extracted | 2 studies · 537 participants | Moderate |
Doxycycline 40 mg vs placebo Time needed until improvement of the skin lesions · Participants with rosacea Interventions for rosacea (2015) · Cochrane | no estimate extracted | 2 studies · 537 participants | High |
Metronidazole vs placebo Duration of remission · Participants with rosacea Interventions for rosacea (2015) · Cochrane | RR 0.5 [0.25, 0.99] | 1 study · 88 participants | Moderate |
Doxycycline 40 mg vs placebo Duration of remission ‐ not measured · Participants with rosacea Interventions for rosacea (2015) · Cochrane | no estimate extracted | NR | No studies |
Azithromycin vs doxycycline 100 mg HRQOL ‐ not measured · Participants with rosacea Interventions for rosacea (2015) · Cochrane | no estimate extracted | NR | No studies |
Azithromycin vs doxycycline 100 mg Participant‐assessed improvement in rosacea severity · Participants with rosacea Interventions for rosacea (2015) · Cochrane | RR 0.98 [0.77, 1.25] | 1 study · 67 participants | Very low |
Azithromycin vs doxycycline 100 mg Proportion of participants with adverse event · Participants with rosacea Interventions for rosacea (2015) · Cochrane | RR 1.62 [0.32, 8.26] | 1 study · 67 participants | Very low |
Azithromycin vs doxycycline 100 mg Physician‐assessed improvement in rosacea severity ‐ not measured · Participants with rosacea Interventions for rosacea (2015) · Cochrane | no estimate extracted | NR | No studies |
Azithromycin vs doxycycline 100 mg Assessment of erythema or telangiectasia ‐ not measured · Participants with rosacea Interventions for rosacea (2015) · Cochrane | no estimate extracted | NR | No studies |
Azithromycin vs doxycycline 100 mg Lesion counts · Participants with rosacea Interventions for rosacea (2015) · Cochrane | no estimate extracted | 1 study · 67 participants | Very low |
Azithromycin vs doxycycline 100 mg Time needed until improvement of the skin lesions ‐ not measured · Participants with rosacea Interventions for rosacea (2015) · Cochrane | no estimate extracted | NR | No studies |
Azithromycin vs doxycycline 100 mg Duration of remission · Participants with rosacea Interventions for rosacea (2015) · Cochrane | no estimate extracted | 1 study · 67 participants | Very low |
Doxycycline 40 mg + metronidazole 1% gel vs doxycycline 100 mg + metronidazole 1% gel HRQOL ‐ not measured · Participants with rosacea Interventions for rosacea (2015) · Cochrane | no estimate extracted | NR | No studies |
Azelaic acid vs placebo HRQOL ‐ not measured · Participants with rosacea Interventions for rosacea (2015) · Cochrane | no estimate extracted | NR | No studies |
Doxycycline 40 mg + metronidazole 1% gel vs doxycycline 100 mg + metronidazole 1% gel Participant‐assessed improvement in rosacea severity ‐ not measured · Participants with rosacea Interventions for rosacea (2015) · Cochrane | no estimate extracted | NR | No studies |
Doxycycline 40 mg + metronidazole 1% gel vs doxycycline 100 mg + metronidazole 1% gel Proportion of participants with adverse event · Participants with rosacea Interventions for rosacea (2015) · Cochrane | RR 0.25 [0.11, 0.54] | 1 study · 91 participants | Low |
Doxycycline 40 mg + metronidazole 1% gel vs doxycycline 100 mg + metronidazole 1% gel Physician‐assessed improvement in rosacea severity Reduction in Investigator's Global Assessment · Participants with rosacea Interventions for rosacea (2015) · Cochrane | no estimate extracted | 1 study · 91 participants | Low |
Doxycycline 40 mg + metronidazole 1% gel vs doxycycline 100 mg + metronidazole 1% gel Assessment of erythema or telangiectasia Clinician's Erythema Assessment · Participants with rosacea Interventions for rosacea (2015) · Cochrane | no estimate extracted | 1 study · 91 participants | Low |
Doxycycline 40 mg + metronidazole 1% gel vs doxycycline 100 mg + metronidazole 1% gel Lesion count · Participants with rosacea Interventions for rosacea (2015) · Cochrane | no estimate extracted | 1 study · 91 participants | Low |